natgillin/translations-raw huggingface dataset:
After a single subcutaneous dose of 25 mg Enbrel, the average maximum serum concentration observed in healthy volunteers was 1.65 ± 0.66 µg/ml, and the area under the curve was 235 ± 96.6 µg•hr/ml. 
Po enkratnem subkutanem odmerku 25 mg zdravila Enbrel je bila povprečna največja koncentracija zdravila v serumu pri zdravih prostovoljcih 1,65  0,66 g/ml, površina pod krivuljo pa 235  96,6 g·h/ml.
No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. 
Podatkov o sekundarnem prenosu okužbe z živimi cepivi pri bolnikih, ki prejemajo zdravilo Enbrel, ni na voljo.
The safety and efficacy of Enbrel in patients with chronic infections have not been evaluated. 
Varnost in učinkovitost zdravila Enbrel pri bolnikih s kroničnimi okužbami nista bili ovrednoteni.
The package leaflet is updated accordingly. 
Skladno s tem je treba posodobiti tudi navodilo za uporabo.
If Enbrel has no effect on the child's condition after 12 weeks, your doctor may tell you to stop using this medicine. 
Če zdravilo Enbrel po 12 tednih nima nobenega učinka na otrokovo stanje, vam bo zdravnik morda naročil, da prenehajte uporabljati to zdravilo.
If the needle is correctly lined up, you should feel a slight resistance and then a “pop” as the needle goes through the centre of the stopper. 
Če držite iglo v pravilnem položaju, boste začutili rahel odpor in potem “pok”, ko bo igla predrla osrednji del zamaška.
After 12 weeks of treatment, patients in the placebo group began treatment with blinded Enbrel (25 mg twice a week); patients in the active treatment groups continued to week 24 on the dose to which they were originally randomised. 
Po 12 tednih zdravljenja so bolniki v skupini s placebom začeli slepo zdravljenje z zdravilom Enbrel (25 mg dvakrat na teden), bolniki v skupinah z aktivnim zdravljenjem pa so do 24. tedna nadaljevali z odmerkom, na katerega so bili prvotno randomizirani.
In clinical trials, no interactions have been observed when Enbrel was administered with glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, or methotrexate. 
Med kliničnimi preskušanji niso opazili nobenih interakcij med zdravilom Enbrel in glukokortikoidi, salicilati (razen sulfasalazina), nesteroidnimi protivnetnimi zdravili (NSAIDs), analgetiki ali metotreksatom.
In a phase II randomised placebo-controlled study of 48 hospitalised patients treated with Enbrel or placebo for moderate to severe alcoholic hepatitis, Enbrel was not efficacious, and the mortality rate in patients treated with Enbrel was significantly higher after 6 months. 
faze, v kateri so proučevali 48 hospitaliziranih bolnikov, zdravljenih z zdravilom Enbrel ali placebom zaradi zmernega do hudega alkoholnega hepatitisa, zdravilo Enbrel ni bilo učinkovito in stopnja smrtnosti bolnikov, zdravljenih z zdravilom Enbrel, je bila po 6 mesecih pomembno večja.
Serious infections affect fewer than 1 in 100 patients treated with Enbrel. 
Med zdravljenjem z zdravilom Enbrel so se resne okužbe pojavile pri manj kot 1 od 100 bolnikov.
In a clinical study of adult patients who were receiving established doses of sulfasalazine, to which Enbrel was added, patients in the combination group experienced a statistically significant decrease in mean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone. 
V klinični študiji odraslih bolnikov, ki so prejemali ustaljene odmerke sulfasalazina, ki mu je bilo dodano zdravilo Enbrel, se je pri bolnikih v skupini s kombinacijo obeh zdravil statistično pomembno zmanjšala povprečna koncentracija belih krvničk v primerjavi s skupinama, zdravljenima samo z zdravilom Enbrel ali samo s sulfasalazinom.
Note - If you are unable to start the injection as described, press the pen more firmly against your skin, then press the grey button again. 
Opozorilo - Če ne morete začeti injiciranja, kakor je opisano, peresnik močneje pritisnite ob kožo in nato znova pritisnite sivi gumb.
If the child has any of the above symptoms he/she may be having an allergic reaction to Enbrel, so you should seek immediate medical attention. 
Če ima otrok kateregakoli od zgoraj navedenih simptomov, ima mogoče alergijsko reakcijo na zdravilo Enbrel, zato morate nemudoma poiskati zdravniško pomoč.
If Enbrel has no effect on your condition after 12 weeks, your doctor may tell you to stop taking this medicine. 
Če zdravilo Enbrel po 12 tednih nima nobenega učinka na vašo bolezen, vam zdravnik lahko naroči, da to zdravilo nehate uporabljati.
After cleaning, do not touch the stopper with your hands. 
Po čiščenju se ga z rokami ne smete več dotikati.
In a group of 7,416 patients treated with Enbrel in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis clinical trials, 18 lymphomas were reported. 
V skupini 7.416 bolnikov, zdravljenih z zdravilom Enbrel v kliničnih preskušanjih revmatoidnega artritisa, psoriatičnega artritisa, ankilozirajočega spondilitisa in psoriaze, so poročali o 18 limfomih.
Of patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the patients remaining on Enbrel continued to improve from month 3 through month 7, while those who received placebo did not improve. 
Od bolnikov, ki so dosegli klinični odziv do 90. dneva in se vključili v drugi del študije, se je pri nekaterih bolnikih, ki so ostali na zdravilu Enbrel, klinično stanje nadalje izboljševalo od 3. do 7. meseca zdravljenja, pri tistih, ki so v drugem delu študije prejemali placebo, pa izboljšanja ni bilo.
Carcinogenicity studies, and standard assessments of fertility and postnatal toxicity, were not performed with Enbrel due to the development of neutralising antibodies in rodents. 
Študij kancerogenosti in standardnih raziskav plodnosti in postnatalne toksičnosti zaradi tvorbe nevtralizirajočih protiteles pri glodalcih niso opravili.
Of the rheumatoid arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed new positive ANA (≥1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%). 
Pri bolnikih z revmatoidnim artritisom, ki so jih testirali na antinuklearna protitelesa (ANA), je bil odstotek tistih, ki so razvili nova pozitivna ANA ( 1:40), večji pri bolnikih, ki so prejemali zdravilo Enbrel (11 %), kot pri tistih, ki so prejemali placebo (5 %).
Compared to placebo, patients with rheumatic diseases treated with Enbrel had a significantly higher incidence of injection site reactions (36% vs. 9%). 
V primerjavi s placebom je bila pri bolnikih z revmatskimi obolenji, zdravljenih z zdravilom Enbrel, pojavnost reakcij na mestu injiciranja pomembno večja (36 % proti 9 %).
Compared to placebo, treatment with Enbrel resulted in significant improvements in the ASAS 20, ASAS 50 and ASAS 70 as early as 2 weeks after the initiation of therapy. 
V primerjavi s placebom je po dajanju zdravila Enbrel prišlo do izboljšanja pri ASAS 20, ASAS 50 in ASAS 70 že v 2 tednih od začetka zdravljenja.
The primary efficacy endpoint in all four studies was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75% improvement in the Psoriasis Area and Severity Index score from baseline) at 12 weeks. 
Primarni opazovani dogodek učinkovitosti v vseh štirih študijah je bil tisti delež bolnikov v vsaki zdravljeni skupini, ki je po 12 tednih dosegel PASI 75 (tj. vsaj 75 % izboljšanje indeksa PASIPsoriasis Area and Severity Index; indeks površine in izrazitosti psoriaze - v primerjavi z izhodiščem).
In a pooled data set of clinical trials, the overall incidence of opportunistic infections was 0.09% for the 15,402 subjects who received Enbrel. 
V združeni zbirki podatkov iz kliničnih preskušanj je bila celokupna pojavnost oportunističnih okužb pri 15.402 bolnikih, ki so prejeli Enbrel, 0,09 %.
The safety and efficacy of Enbrel in patients with immunosuppression have not been evaluated. 
Varnost in učinkovitost zdravila Enbrel pri bolnikih z imunosupresijo nista bili ovrednoteni.
Physicians should use caution when using Enbrel in patients who also have moderate to severe alcoholic hepatitis. 
Zdravniki naj bodo pazljivi, kadar uporabljajo zdravilo Enbrel pri bolnikih, ki imajo tudi zmeren do hud alkoholni hepatitis.
The proportion of patients treated with Enbrel who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. 
Delež bolnikov, ki so razvili protitelesa proti kardiolipinu, je bil podobno povečan pri zdravilu Enbrel v primerjavi s placebom.
Enbrel + Methotrexate (n = 231) 
zdravilo Enbrel + metotreksat (n = 231)
Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. 
Zdravilo Enbrel je indicirano tudi za zdravljenje hudega, aktivnega in napredujočega revmatoidnega artritisa pri odraslih, ki še niso dobivali metotreksata.
Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. 
Zdravilo Enbrel je mogoče uporabiti kot monoterapijo, kadar bolnik ne prenese metotreksata ali kadar trajno zdravljenje z metotreksatom ni primerno.
• Check your syringe contains 1 ml of water for injections. 
Preverite, ali brizga vsebuje 1 ml vode za injekcije.
Patients treated with Enbrel should be given the Patient Alert Card. 
Bolniki, ki se zdravijo z zdravilom Enbrel, naj prejmejo opozorilno kartico za bolnika.
Enbrel showed statistically significantly greater improvement from baseline to week 12 compared to placebo in most health-related quality of life and physical function assessments, including BASFI (Bath Ankylosing Spondylitis Functional Index), EuroQol 5D Overall Health State Score and SF-36 Physical Component Score. 
Pokazali so, da je zdravilo Enbrel od izhodišča do 12 tednov statistično pomembno izboljšalo večino ocen z zdravjem povezane kakovosti življenja in telesne funkcije, vključno z BASFI (BASFI - Bath Ankylosing Spondylitis Functional Index; indeks Bath za ocenjevanje aktivnosti ankilizirajočega spondilitisa), rezultatom splošnega zdravstvenega stanja EuroQol 5D in rezultatom telesne komponente SF-36, v primerjavi s placebom.
TNF-antagonists, such as Enbrel, affect the immune system and their use may affect the body's defenses against infection and cancer. 
Antagonisti TNF, kot je zdravilo Enbrel, vplivajo na imunski sistem in lahko zmanjšajo sposobnost organizma za obrambo pred okužbami in rakom.
The long-term safety and effectiveness of Enbrel 0.8 mg/kg (up to 50 mg) once weekly was assessed in an open-label extension study of 181 paediatric subjects with plaque psoriasis for up to 2 years beyond the 48 week study discussed above. 
Dolgoročna varnost in učinkovitost zdravila Enbrel, v odmerkih 0,8 mg/kg (do 50 mg) enkrat na teden, je bila ovrednotena v odprti podaljšani študiji, v kateri je sodelovalo 181 otrok s psoriazo v plakih, ki so se zdravili do 2 leti po zaključku 48-tedenske študije, navedene zgoraj.
The use of Enbrel is not expected to affect the ability to drive or use machines. 
Ni pričakovati, da bi zdravilo Enbrel vplivalo na sposobnost upravljanja vozil in strojev.
Such patients should be investigated urgently, including full blood count; if blood dyscrasias are confirmed, Enbrel should be discontinued. 
Take bolnike je treba nemudoma pregledati, vključno s pregledom celotne krvne slike, in v primeru krvne diskrazije prekiniti zdravljenje s tem zdravilom.
Several adverse events were reported more commonly in 69 juvenile idiopathic arthritis patients receiving 3 months of Enbrel compared to the 349 adult rheumatoid arthritis patients. 
Nekateri neželeni učinki so bili pogosteje opaženi pri 69 bolnikih z juvenilnim idiopatskim artritisom, ki so zdravilo Enbrel prejemali 3 mesece, kot pri 349 odraslih bolnikih z revmatoidnim artritisom.
Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with Varicella Zoster Immune Globulin. 
Bolniki, ki so zelo izpostavljeni virusu noric, naj začasno prekinejo zdravljenje z zdravilom Enbrel, v poštev pa pridejo tudi za profilaktično zdravljenje z imunoglobulinom proti virusu varicella-zoster.
The differences in TSS and JSN were not statistically significant between methotrexate and Enbrel 25 mg. 
Razlike v ocenah TSS in JSN med metotreksatom in 25 mg zdravila Enbrel niso bile statistično pomembne.
• Wegener's granulomatosis: Enbrel is not recommended for the treatment of Wegener's granulomatosis, a rare inflammatory disease. 
Wegenerjeva granulomatoza: Zdravilo Enbrel ni priporočljivo za zdravljenje redke vnetne bolezni Wegenerjeve granulomatoze.
Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. 
Zdravilo Enbrel je v kombinaciji z metotreksatom indicirano za zdravljenje zmernega do hudega aktivnega revmatoidnega artritisa pri odraslih, kadar odziv na zdravljenje z imunomodulirajočimi antirevmatičnimi zdravili, vključno z metotreksatom (če ta ni kontraindiciran), ni zadosten.
Long-term safety of Enbrel monotherapy (n=103), Enbrel plus methotrexate (n=294), or methotrexate monotherapy (n=197) were assessed for up to 3 years in a registry of 594 children aged 2 to 18 years with juvenile idiopathic arthritis, 39 of whom were 2 to 3 years of age. 
Dolgoročno varnost zdravljenja z zdravilom Enbrel v monoterapiji (n = 103), zdravljenja z zdravilom Enbrel v kombinaciji z metotreksatom (n = 294) ali zdravljenja z metotreksatom v monoterapiji (n = 197) so ovrednotili za obdobje do 3 let na osnovi registra 594 otrok, starih od 2 do 18 let, z juvenilnim idiopatskim artritisom.
The long-term safety of Enbrel in combination with other disease-modifying antirheumatic drugs (DMARD) has not been established. 
Varnost dolgotrajnega kombiniranega zdravljenja z zdravilom Enbrel in drugimi imunomodulirajočimi antirevmatičnimi zdravili (DMARD - Disease-Modifying AntiRheumatic Drugs) ni bila ugotovljena.
There were no differences in rates of infection among patients treated with Enbrel and those treated with placebo for plaque psoriasis in placebo-controlled trials of up to 24 weeks duration. 
V stopnjah pogostnosti okužb med bolniki, zdravljenimi z zdravilom Enbrel, in tistimi, ki so prejemali placebo za zdravljenje psoriaze v plakih, v preskušanjih, nadzorovanih s placebom, ki so trajala do 24 tednov, ni bilo razlik.
In adults (aged 18 and over), Enbrel can be used for moderate or severe rheumatoid arthritis, psoriatic arthritis, severe axial spondyloarthritis including ankylosing spondylitis, and moderate or severe psoriasis - in each case usually when other widely used treatments have not worked well enough or are not suitable for you. 
Pri odraslih (starih 18 let in več) se zdravilo Enbrel lahko uporablja pri zdravljenju zmernega ali hudega revmatoidnega artritisa, psoriatičnega artritisa, hudega aksialnega spondilartritisa, vključno z ankilozirajočim spondilitisom, in zmerne ali hude luskavice - v vseh primerih običajno šele po neuspešnem zdravljenju z drugimi običajnimi oblikami zdravljenja, ali če te oblike zdravljenja za vas niso primerne.
You or the child should not use Enbrel with medicines that contain the active substance anakinra or abatacept. 
Zdravila Enbrel vi ali otrok ne smete jemati skupaj z zdravili, ki vsebujejo učinkovino anakinro ali abatacept.
If you have any questions, please talk to a doctor, nurse or pharmacist who is familiar with Enbrel. 
Če imate kakršnakoli vprašanja, se posvetujte z zdravnikom, medicinsko sestro ali farmacevtom, ki dobro poznajo zdravilo Enbrel.
Withdrawing the Enbrel solution from the vial f. 
Jemanje raztopine zdravila Enbrel iz viale f.
Adjusted mean change from baseline was 3.8 for Enbrel treated (n=95) versus 0.8 for placebo treated (n=105) patients (p<0.001). 
Prilagojena povprečna sprememba od izhodišča je bila 3,8 pri bolnikih, zdravljenih z zdravilom Enbrel (n = 95), in 0,8 pri bolnikih, ki so prejemali placebo (n = 105) (p < 0,001).
How to use Enbrel 
Kako uporabljati zdravilo Enbrel
Combining the results of controlled clinical trials, more cases of NMSC were observed in patients receiving Enbrel compared with control patients, particularly in patients with psoriasis. 
Pri združevanju rezultatov nadzorovanih kliničnih preskušanj so opazili več primerov NMSC pri bolnikih, ki so prejemali zdravilo Enbrel, kot pri kontrolnih bolnikih, še zlasti pri bolnikih s psoriazo.
Do not insert the needle at an angle, this may cause the needle to bend and/or prevent proper addition of the solvent into the vial (see Diagram 4). 
Igle ne zabodite pod kotom, ker bi jo lahko tako ukrivili in/ali s tem preprečili pravilno dovajanje vehikla v vialo (glejte sliko 4).
Your doctor will decide how long you should take Enbrel and whether retreatment is needed based on your response. 
Zdravnik bo na podlagi vašega odziva na zdravilo določil, koliko časa morate uporabljati zdravilo Enbrel in ali je potrebno ponovno zdravljenje.
Enbrel powder for solution must be reconstituted in 1 ml of solvent before use (see section 6.6). 
Pred uporabo je treba Enbrel prašek za raztopino za injiciranje rekonstituirati v 1 ml vehikla (glejte poglavje 6.6).
There is no known antidote to Enbrel. 
Znanega antidota za zdravilo Enbrel ni.
One hundred and twenty-nine (129) new malignancies of various types were observed in 4,114 rheumatoid arthritis patients treated in clinical trials with Enbrel for up to approximately 6 years, including 231 patients treated with Enbrel in combination with methotrexate in the 2-year active-controlled study. 
Sto devetindvajset (129) novih malignih obolenj različnih tipov so ugotovili pri 4.114 bolnikih z revmatoidnim artritisom, zdravljenih v kliničnih preskušanjih z zdravilom Enbrel do približno 6 let, vključno z 231 bolniki, ki so bili zdravljeni s kombinacijo zdravila Enbrel in metotreksata v dvoletni študiji, nadzorovani z učinkovino.
Enbrel should be discarded if not used within four weeks after removal from the refrigerator. 
Zdravilo Enbrel zavrzite, če ga ne porabite v štirih tednih po odvzemu iz hladilnika.
Enbrel (n = 223) 
zdravilo Enbrel (n = 223)
In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with Enbrel developed injection site reactions compared with 3.4% of placebo-treated patients during the first 12 weeks of treatment. 
V nadzorovanih preskušanjih bolnikov s psoriazo v plakih so se reakcije na mestu injiciranja v prvih 12 tednih zdravljenja pojavile pri približno 13,6 % bolnikov, zdravljenih z zdravilom Enbrel, in pri 3,4 % bolnikov, ki so dobivali placebo.
• Use a new alcohol swab to clean the grey stopper on the Enbrel vial. 
Z novo alkoholno blazinico očistite sivi gumijasti zamašek na viali.
As the liquid level drops in the vial, you may need to withdraw the needle partially to keep the tip of the needle in the liquid. 
Ko se raven raztopine v viali zniža, morate iglo deloma izvleči, da bo konica igle ostala v tekočini.
If you forget to inject Enbrel 
Če ste pozabili injicirati zdravilo Enbrel
Mannitol (E421) Sucrose Trometamol 
Prašek manitol (E421) saharoza trometamol
Enbrel is supplied with pre-filled syringes containing water for injection. 
Zdravilu Enbrel je priložena napolnjena injekcijska brizga, ki vsebuje vodo za injekcije.
In a double-blind, placebo-controlled, randomised clinical study in adult patients with psoriatic arthritis, 184 patients also received a multivalent pneumococcal polysaccharide vaccine at week 4. 
V dvojno slepi s placebom nadzorovani randomizirani klinični študiji pri odraslih bolnikih s psoriatičnim artritisom je 184 bolnikov v 4. tednu dobilo tudi multivalentno polisaharidno cepivo proti pnevmokokom.
• Remove the plastic cap from the Enbrel vial (see Diagram 1). 
Z viale zdravila Enbrel odstranite plastično zaporko (glejte sliko 1).
Adding water for injections 
Dodajanje vode za injekcije
Slowly press the plunger to push bubbles out of the syringe and into the vial. 
Počasi pritisnite na bat, da iztisnete mehurčke iz brizge v vialo.
The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 205 patients with psoriatic arthritis. 
Učinkovitost zdravila Enbrel je bila ocenjena v randomizirani, dvojno slepi in s placebom nadzorovani študiji pri 205 bolnikih s psoriatičnim artritisom.
Enbrel was considered to be non-genotoxic from a battery of in vitro and in vivo studies. 
Zdravilo Enbrel se ni izkazalo za genotoksičnega v vrsti študij in vivo in in vitro.
One rheumatoid arthritis patient mistakenly self-administered 62 mg Enbrel subcutaneously twice weekly for 3 weeks without experiencing undesirable effects. 
En bolnik z revmatoidnim artritisom si je pomotoma subkutano injiciral 62 mg zdravila Enbrel 2-krat tedensko 3 tedne, pri tem pa ni prišlo do pojava kakršnegakoli neželenega učinka.
T oxic epidermal necrolysis 
toksična epidermalna nekroliza
Administration of Enbrel should be discontinued if a patient develops a serious infection. 
Zdravljenje z zdravilom Enbrel je treba prekiniti, če pride do resne okužbe.
Additionally, studies have not been conducted to assess the effects of discontinuing or reducing the recommended dose of Enbrel following its long-term use in patients with JIA. 
Pri bolnikih z JIA prav tako niso izvedli študij za ovrednotenje učinka prekinitve zdravljenja ali zmanjšanja priporočenega odmerka zdravila Enbrel po njegovi dolgotrajni uporabi.
Some have occurred within a few weeks after initiating treatment with Enbrel in patients who have underlying conditions (e.g., diabetes, congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis (see section 4.4). 
Nekatere okužbe so se pojavile nekaj tednov po začetku zdravljenja bolnikov, ki so imeli poleg revmatoidnega artritisa tudi druga obolenja (npr. sladkorno bolezen, kongestivno srčno popuščanje, aktivne ali kronične okužbe v anamnezi) (glejte poglavje 4.4).
If re-treatment with Enbrel is indicated, the above guidance on treatment duration should be followed. 
Če je indicirano ponovno zdravljenje z zdravilom Enbrel, se ravnamo po zgornjih smernicah glede trajanja zdravljenja.
Enbrel N = 138 
Zdravilo Enbrel N = 138
From the start of part 2, the median time to flare was ≥ 116 days for patients who received Enbrel and 28 days for patients who received placebo. 
Od začetka drugega dela študije je bil mediani čas do ponovnega izbruha bolezni  116 dni pri bolnikih na zdravilu Enbrel in 28 dni pri bolnikih na placebu.
In a group of 2,711 plaque psoriasis patients treated with Enbrel in double-blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin cancers were reported. 
V skupini 2.711 bolnikov s psoriazo v plakih, zdravljenih z zdravilom Enbrel v dvojno slepih in odprtih študijah, ki so trajale do 2,5 leta, so poročali o 30 malignomih in 43 primerih nemelanomskega kožnega raka.
In part 2, 6 of 25 (24%) patients remaining on Enbrel experienced a disease flare compared to 20 of 26 (77%) patients receiving placebo (p=0.007). 
V drugem delu je 6 od 25 (24 %) bolnikov, ki so ostali na zdravilu Enbrel, doživelo ponoven izbruh bolezni, v primerjavi z 20 od 26 (77 %) bolnikov, ki so v drugem delu prejemali placebo (p = 0,007).
There have been reports of hypoglycaemia following initiation of Enbrel in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients. 
Hipoglikemija pri bolnikih, ki se zdravijo zaradi sladkorne bolezni Po uvedbi zdravila Enbrel so pri bolnikih, ki so prejemali zdravila za zdravljenje sladkorne bolezni, poročali o hipoglikemiji, zaradi katere je bilo treba pri nekaterih od teh bolnikov zmanjšati odmerek zdravila za zdravljenje sladkorne bolezni.
What Enbrel looks like and contents of the pack 
Izgled zdravila Enbrel in vsebina pakiranja
24 Months 
24 mesecev